An Overview of Pharmacological and Non-Pharmacological Treatment as a Useful Tool for the Protection from Cardiotoxicity of Antineoplastic Drugs

Tanja Radonjic; Nina Simonovic; Tamara Nikolic Turnic

doi:10.2478/sjecr-2018-0019

.blurhash-client-img { display: none !important; }

An Overview of Pharmacological and Non-Pharmacological Treatment as a Useful Tool for the Protection from Cardiotoxicity of Antineoplastic Drugs

EABR. Experimental and Applied Biomedical Research

Volume 21 (2020): Issue 3 (September 2020)

By: Tanja Radonjic, Nina Simonovic and Tamara Nikolic Turnic

Open Access

|Dec 2020

Abstract

Unfortunately, in patients with cancer disease, clinical application of antineoplastic drug results in severe side effects of cardiotoxicity.

We aim to review the research focused on elimination or reduction of antineoplastic drug-induced cardiotoxicity without affecting its anticancer efficacy by different agens.

This study is based on pertinent papers that were retrieved by a selective search using relevant keywords in PubMed and ScienceDirect. Based on mentioned purpose, various strategies were investigated and proposed, and thousands of compounds were screened. The literature mainly focusing on drugs, natural products and herb extracts with therapeutic efficacies as well as non-pharmacological treatment against differently induced cardiotoxicity during treatment in patients with cancers.

Larger future studies are necessary to reach a point of secure cytostatic therapy, improved patient survival and quality of life. Until that moment, baseline and serial cardiac evaluation is recommended to facilitate early identification and treatment of cardiotoxicity.

References

1. Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics, Accessed: May, 2018.
Search in Google Scholar Back to article
2. Ilic M, Ilic I. Cancer mortality in Serbia, 1991-2015: an age-period-cohort and joinpoint regression analysis. Cancer Commun (Lond). 2018 Apr 10;38(1):10.10.1186/s40880-018-0282-3
Search in Google Scholar Back to article
3. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.10.1093/jnci/djp440
Search in Google Scholar Back to article
4. Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L’Allemain G, Bay JO. [Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer]. Bull Cancer. 2018;105(1):6-14.10.1016/j.bulcan.2017.11.006
Search in Google Scholar Back to article
5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263-302.10.2165/00002018-200022040-00002
Search in Google Scholar Back to article
6. Albini A, Pannesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.10.1093/jnci/djp440
Search in Google Scholar Back to article
7. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21:173–179.10.1093/annonc/mdq295
Search in Google Scholar Back to article
8. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213–220.10.1016/j.jacc.2009.03.095
Search in Google Scholar Back to article
9. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracicline therapy. JAMA. 1991;266:1672–1677.10.1001/jama.1991.03470120074036
Search in Google Scholar Back to article
10. Stevens PL, Lenihan DJ. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers. Curr Cardiol Rep. 2015 Jul;17(7):603.10.1007/s11886-015-0603-y
Search in Google Scholar Back to article
11. ltena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391–399.10.1016/S1470-2045(09)70042-7
Search in Google Scholar Back to article
12. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basicunder-lying mechanisms. Pharmacol Ther. 2018; S0163-7258(18)30072-X.10.1016/j.pharmthera.2018.04.009
Search in Google Scholar Back to article
13. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Ver-rill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.10.1186/1471-2407-10-337
Search in Google Scholar Back to article
14. SNPC. European Medicine Agency. Available in: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000682/human_med_001047.jsp&mid=WC0b01ac058001d124
Search in Google Scholar Back to article
15. Cvetkovic RS, Scott LJ. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemo-therapy. Drugs. 2005;68:1005–1024.
Search in Google Scholar Back to article
16. Csapo M, Lazar L. Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention. Clujul Medical. 2014;87(3):135-142.
Search in Google Scholar Back to article
17. SNPC. Food and Drug Agency. Available in: https://www.fda.gov/Drugs; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020212
Search in Google Scholar Back to article
18. Boucek RJ, Jr, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3:319–29.10.1385/CT:3:4:319
Search in Google Scholar Back to article
19. Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469–73.10.1002/jat.78211746193
Search in Google Scholar Back to article
20. Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142:396–403.10.1016/j.jtcvs.2010.07.097317351221094500
Search in Google Scholar Back to article
21. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60:373–81.10.1016/j.phrs.2009.05.00719467331
Search in Google Scholar Back to article
22. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 2013; 61: 2355–2362.10.1016/j.jacc.2013.02.07223583763
Search in Google Scholar Back to article
23. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009; 69: 695–699.10.1158/0008-5472.CAN-08-307619147586
Search in Google Scholar Back to article
24. Gnad R, Kaina B, Fritz G. Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. Exp Cell Res 2001; 264: 244–249.10.1006/excr.2001.516511262181
Search in Google Scholar Back to article
25. Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2011; 2: e190.10.1038/cddis.2011.65318141521833028
Search in Google Scholar Back to article
26. Ramanjaneyulu SV, Trivedi PP, Kushwaha S, Vikram A, Jena GB. Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. J Physiol Biochem 2013; 69: 513–525.10.1007/s13105-013-0240-0
Search in Google Scholar Back to article
27. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.10.1007/s11897-017-0353-9
Search in Google Scholar Back to article
28. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.10.1016/j.jacc.2006.07.052
Search in Google Scholar Back to article
29. Pimprapa V, Edward Y. Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities. Journal of the American College of Cardiology. 2014; 64(9): 938-945.10.1016/j.jacc.2014.06.1167
Search in Google Scholar Back to article
30. Mônica Samuel Avila, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Vagner Oliveira Carvalho Rigaud, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity Journal of the American College of Cardiology. 2018; 71 (20) 2281-2290.10.1016/j.jacc.2018.02.049
Search in Google Scholar Back to article
31. Purva Sharma, Stephanie Hakimian, Juan Camacho and Robert Chait. Prevention of chemo-induced cardiotoxicity with beta-blockers. Journal of the American College of Cardiology, 2018;71(11); DOI: 10.1016/S0735-1097(18)32344-1.10.1016/S0735-1097(18)32344-1
Search in Google Scholar Back to article
32. Escudier B, Alexandre JB, Leclercq B, Morin P, Guyot JM, Nitenberg G. Cardiotoxicitt du 5-fluorouracil. Caract Cristiques, mkanisme, conduite pratique. Presse Med 1986; 15:6-11.
Search in Google Scholar Back to article
33. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.10.1016/j.jacc.2009.02.05019520246
Search in Google Scholar Back to article
34. Puel C, Mathey J, Agalias A, Kati-Coulibaly S, Mardon J, et al. Dose–response study of effect of oleuropein, an olive oil polyphenol, in an ovariectomy/inflammation experimental model of bone loss in the rat. Clin. Nutr 2006; 25, 859–868.10.1016/j.clnu.2006.03.00916740345
Search in Google Scholar Back to article
35. Gülkaç MD, Akpinar G, Ustün H, Ozön Kanli A. Effects of vitamin A on doxorubicin-induced chromosomal aberrations in bone marrow cells of rats. Mutagenesis 2004; 19, 231–236.10.1093/mutage/geh02115123789
Search in Google Scholar Back to article
36. Santos RV, Batista Jr, ML, Caperuto EC, Costa Rosa LF. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats. Clin. Exp. Pharmacol. Physiol. 2007; 34:1294–1299.
Search in Google Scholar Back to article
37. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther 2005; 4:110–130.10.1177/153473540527619115911925
Search in Google Scholar Back to article
38. Huertas JR, Battino M, Lenaz G, Mataix FJ. Changes in mitochondrial and microsomal rat liver coenzyme Q9 and Q10 content induced by dietary fat and endogenous lipid peroxidation. FEBS Lett. 1991; 287:89–92.10.1016/0014-5793(91)80022-U
Search in Google Scholar Back to article
39. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 2009;486:95–102.
Search in Google Scholar Back to article
40. Goulas V, Exarchou V, Troganis AN, Psomiadou E, Fotsis T, Briasoulis E, Gerothanassis IP. Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells. Mol. Nutr. Food Res. 2009; 53, 600–608.
Search in Google Scholar Back to article
41. Quiles JL, Huertas JR, Battino M, Mataix J, Ramírez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002; 180:79–95.10.1016/S0300-483X(02)00383-9
Search in Google Scholar Back to article
42. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK. Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol. 2003; 3:16–24.10.1186/1471-2210-3-1632440114687418
Search in Google Scholar Back to article
43. Lim HA, Kim JH, Kim JH, Sung MK, Kim MK, Park, JH, Kim JS. Genistein induces glucose-regulated protein 78 in mammary tumor cells. J. Med. Food 2006; 9:28–32.
Search in Google Scholar Back to article
44. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr. Rev. 2008; 66:445–454.
Search in Google Scholar Back to article
45. Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, Aydin A, et al. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol. Trace Elem. Res. 2009; 14:25-31.
Search in Google Scholar Back to article
46. Bulucu F, Oktenli C, Kenar L, Ocal R, Koc B, Inal V, Yamanel L, Yaman H, Sanisoglu YS, Aydin A. Efficacy of deferoxamine, N-acetylcysteine and selenium treatments in rats with adriamycin-induced nephrotic syndrome. J. Nephrol. 2008; 21: 576–583.
Search in Google Scholar Back to article
47. Jemai H, El Feki A, Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats. J. Agric. Food Chem. 2009; 57:8798–8804.10.1021/jf901280r19725535
Search in Google Scholar Back to article
48. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008; 259:111–118.10.1016/j.canlet.2007.10.00318006147
Search in Google Scholar Back to article
49. Monstrey SJ, Mullick P, Narayanan K, et al. Hyperbaric oxygen therapy and free radical production: An experimental study in doxorubicin (Adriamycin) extravasation injuries. Ann Plast Surg 1997; 38:163-168.10.1097/00000637-199702000-000119043586
Search in Google Scholar Back to article
50. Akta S, Toklu AS, Olgac V. Hyperbaric oxygen therapy in Adriamycin extravasation: An experimental animal study. Ann Plast Surg 2000; 45:167-171.10.1097/00000637-200045020-0001210949345
Search in Google Scholar Back to article
51. Karagoz B, Suleymanoglu S, Uzun G, Bilgi O, Aydinoz S, Haholu A, Turken O,Onem Y, Kandemir EG. Hyper-baric oxygen therapy does not potentiatedoxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol. 2008;102(3):287-92.10.1111/j.1742-7843.2007.00196.x18248515
Search in Google Scholar Back to article
52. Goolsby, Tiffany V. et al. Extravasation of Chemotherapeutic Agents: Prevention and TreatmentSeminars in Oncology. 2006; 33(1); 139-143.10.1053/j.seminoncol.2005.11.00716473651
Search in Google Scholar Back to article
53. Newton RU, Galvão DA. Exercise in prevention and management of cancer. Curr Treat Options Oncol. 2008;9(2-3):135-46.10.1007/s11864-008-0065-118704691
Search in Google Scholar Back to article
54. Rajarajeswaran P, Vishnupriya R. Exercise in cancer. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology. 2009;30(2):61-70.10.4103/0971-5851.60050288588220596305
Search in Google Scholar Back to article
55. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.10.1007/s11897-017-0353-928779279
Search in Google Scholar Back to article
56. Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. Jpn J Clin Oncol. 2016;34:2743–9.10.1200/JCO.2015.65.6603501974627217451
Search in Google Scholar Back to article
57. Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res. 2009; 15:4963–7.10.1158/1078-0432.CCR-09-062819622583
Search in Google Scholar Back to article
58. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology - Heart and Circula-tory Physiology. 2015; 309(9):H1453-H1467.10.1152/ajpheart.00554.2015466697426386112
Search in Google Scholar Back to article
59. Fandeev OA, Vasechkin SS, Alekhin MN, Odintsov SV, Kallistov VE, Sidorenko BA. Clinical value of antracycline toxicity: modern approaches to diagnosis,prevention, and treatment. Kardiologiia. 2011; 51(7):40-6.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/sjecr-2018-0019 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454

Journal RSS Feed

Language: English

Page range: 263 - 270

Submitted on: Jun 3, 2018

Accepted on: Jun 9, 2018

Published on: Dec 21, 2020

Published by: University of Kragujevac, Faculty of Medical Sciences

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

cardiotoxicity,

anti-neoplastic therapy,

pharmacological,

herbal,

natural cardioprotection,

Related subjects:

Clinical medicine, other

© 2020 Tanja Radonjic, Nina Simonovic, Tamara Nikolic Turnic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 21 (2020): Issue 3 (September 2020)